Arcutis (ARQT) Q2 Revenue Soars 164%

Arcutis Biotherapeutics (NASDAQ:ARQT), a dermatology-focused pharmaceutical company, reported earnings results on August 6, 2025. Highlights included strong revenue growth and improved earnings, significantly outperforming Wall Street expectations, with GAAP revenue of $81.5 million and GAAP EPS of $0.13, both exceeding analyst estimates. Revenue (GAAP) climbed to $81.5 million, topping analyst forecasts of $73.69 million (GAAP). The company also posted a narrower net loss per share of $(0.13) (GAAP), which came in ahead of estimates by $0.28 (GAAP). This result marks a notable improvement compared to the $(0.42) loss per share (GAAP) in Q2 2024. The quarter demonstrated solid execution in product launches and market expansion, notably for its leading ZORYVE dermatology portfolio.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

Arcutis Biotherapeutics is a biopharmaceutical firm dedicated to creating and commercializing treatments for chronic skin conditions. Its primary product family, ZORYVE, features a range of topical therapies: creams and foam based on the phosphodiesterase-4 (PDE4) inhibitor roflumilast. ZORYVE is approved for multiple indications, including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The franchise targets both adult and pediatric markets.

Continue reading

Source Fool.com